Inhibikase Therapeutics IKT
NASDAQ IKT
$1.60 -0.08 (-4.76%)
As of: Nov 10, 2026 · 3:27 PM EST

Inhibikase Therapeutics (IKT) Net Long-Term Debt Issued (Repaid) (2020 - 2022)

Updated

Inhibikase Therapeutics' Non-Current Debt came in at $248,911 for Q2 2021, unchanged from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Net Long-Term Debt Issued (Repaid) (2020 - 2022) Analysis & Trends

At the end of FY2020, Inhibikase Therapeutics' Non-Current Debt was $276,461.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net LT Debt (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -1.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 9.98 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -19.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Inhibikase Therapeutics 275.82 Mn -309.65 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 -248,911.00
Jun 30, 2021 367,128.00
Mar 31, 2021 -409,662.00
Jun 30, 2020 27,550.00
Mar 31, 2020 245,250.00
API Access

Inhibikase Therapeutics Net Long-Term Debt Issued (Repaid) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=IKT&period=max&api_key=YOUR_API_KEY